- Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor.
-
Inhibitors of the MAP kinase p38 provide a novel approach for the treatment of osteoporosis, inflammatory disorders, and cancer. We have identified N-(3-tert-butyl-1-methyl-5-pyrazolyl)-N'-(4-(4-pyridinylmethyl)phenyl)urea as a potent and selective p38 ki
- Dumas, Jacques,Hatoum-Mokdad, Holia,Sibley, Robert N,Smith, Roger A,Scott, William J,Khire, Uday,Lee, Wendy,Wood, Jill,Wolanin, Donald,Cooley, Jeffrey,Bankston, Donald,Redman, Aniko M,Schoenleber, Robert,Caringal, Yolanda,Gunn, David,Romero, Romulo,Osterhout, Martin,Paulsen, Holger,Housley, Timothy J,Wilhelm, Scott M,Pirro, John,Chien, Du-Shieng,Ranges, Gerald E,Shrikhande, Alka,Muzsi, Andrew,Bortolon, Elizabeth,Wakefield, Jean,Gianpaolo Ostravage, Cynthia,Bhargava, Ajay,Chau, Thuy
-
-
Read Online
- Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators
-
The evolution of gamma-secretase modulators (GSMs) through the introduction of novel heterocycles with the goal of aligning activity for reducing the levels of Aβ42 and properties consistent with a drug-like molecule are described. The insertion of a methoxypyridine motif within the tetracyclic scaffold provided compounds with improved activity for arresting Aβ42 production as well as improved properties, including solubility. In vivo pharmacokinetic analysis demonstrated that several compounds within the novel series were capable of crossing the BBB and accessing the therapeutic target. Treatment with methoxypyridine-derived compound 64 reduced Aβ42 levels in the plasma of J20 mice, in addition to reducing Aβ42 levels in the plasma and brain of Tg2576 mice.
- Barnes, Keith D.,Buckle, Ronald N.,Chen, Xinchao,Herr, R. Jason,Johnson, Graham,Lin, Juinn H.,Mayhew, Nicholas J.,Mobley, William C.,Nguyen, Phuong,Paquette, William D.,Rynearson, Kevin D.,Sakwa, Samuel A.,Tanzi, Rudolph E.,Wagner, Steven L.,Yang, Jinhai
-
-
- Pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists
-
A series of 1-substituted 3-(t-butyl/trifluoromethyl)pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonamidophenyl)propanamides were investigated for hTRPV1 antagonism. The structure activity relationship indicated that the 3-chlorophenyl group at the 1-position of pyrazole was the optimized hydrophobic group for antagonistic potency and the activity was stereospecific to the S-configuration, providing exceptionally potent antagonists 13S and 16S with Ki(CAP) = 0.1 nM. Particularly significant, 13S exhibited antagonism selective for capsaicin and NADA and not for low pH or elevated temperature. Both compounds also proved to be very potent antagonists for rTRPV1, blocking in vivo the hypothermic action of capsaicin, consistent with their in vitro mechanism. The docking study of compounds 13S and 16S in our hTRPV1 homology model indicated that the binding modes differed somewhat, with that of 13S more closely resembling that of GRT12360.
- Lee, Sunho,Kim, Changhoon,Ann, Jihyae,Thorat, Shivaji A.,Kim, Eunhye,Park, Jongmi,Choi, Sun,Blumberg, Peter M.,Frank-Foltyn, Robert,Bahrenberg, Gregor,Stockhausen, Hannelore,Christoph, Thomas,Lee, Jeewoo
-
p. 4383 - 4388
(2017/09/12)
-
- Design and synthesis of aminothiazole modulators of the gamma-secretase enzyme
-
The design and construction of a series of novel aminothiazole-derived γ-secretase modulators is described. The incorporation of heterocyclic replacements of the terminal phenyl D-ring of lead compound 1 was conducted in order to align potency with favorable drug-like properties. γ-Secretase modulator 28 displayed good activity for in vitro inhibition of Aβ42, as well as substantial improvement in ADME and physicochemical properties, including aqueous solubility. Pharmacokinetic evaluation of compound 28 in mice revealed good brain penetration, as well as good clearance, half-life, and volume of distribution which collectively support the continued development of this class of compounds.
- Rynearson, Kevin D.,Buckle, Ronald N.,Barnes, Keith D.,Herr, R. Jason,Mayhew, Nicholas J.,Paquette, William D.,Sakwa, Samuel A.,Nguyen, Phuong D.,Johnson, Graham,Tanzi, Rudolph E.,Wagner, Steven L.
-
supporting information
p. 3928 - 3937
(2016/08/01)
-
- Biophysical investigation and conformational analysis of p38α kinase inhibitor doramapimod and its analogues
-
Doramapimod (BIRB 796) is a potent inhibitor of p38α mitogen-activated protein kinase. It contains an aryl-pyrazole scaffold as a pharmacophore critical for binding. The aryl-pyrazole scaffold is not planar and adopts an out-of-plane conformation, which is described by the torsion angle θ. In this letter, we report the chemical synthesis and biophysical characterization of different analogues of doramapimod (3-12) exhibiting distinctly different aryl-pyrazole torsion angle θ values. The torsion angle θ values of the synthesized analogues (3-6) were determined by crystal structural analysis and the binding affinities to p38α kinase investigated by microscale thermophoresis. Our results unveil a clear correlation between kinase binding and the torsion angle θ of tested doramapimod analogues, highlighting the importance of inhibitor conformation for protein binding.
- Nasiri, Amir H.,Saxena, Krishna,Bats, Jan W.,Nasiri, Hamid R.,Schwalbe, Harald
-
p. 1421 - 1428
(2016/07/21)
-
- Drug Discovery against Psoriasis: Identification of a New Potent FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor, 1-(4-((1H-Pyrazolo[3,4-d]pyrimidin-4-yl)oxy)-3-fluorophenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea, That Showed Potent Activity in a Psoriatic Animal Model
-
Psoriasis is a chronic T-cell-mediated autoimmune disease, and FMS-like tyrosine kinase 3 (FLT3) has been considered as a potential molecular target for the treatment of psoriasis. In this investigation, structural optimization was performed on a lead compound, 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea (1), which showed a moderate inhibitory activity againt FLT3. A series of pyrazolo[3,4-d]pyrimidine derivatives were synthesized, and structure-activity relationship analysis led to the discovery of a number of potent FLT3 inhibitors. One of the most active compounds, 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)-3-fluorophenyl)-3-(5-tert-butylisoxazol-3-yl)urea (18b), was then chosen for in-depth antipsoriasis studies because this compound displayed the highest potency in a preliminary antipsoriasis test. Compound 18b exhibited significant antipsoriatic effects in the K14-VEGF transgenic mouse model of psoriasis, and no recurrence was found 15 days later after the last administration. Detailed mechanisms of action of compound 18b were also investigated. Collectively, compound 18b could be a potential drug candidate for psoriasis treatment.
- Li, Guo-Bo,Ma, Shuang,Yang, Ling-Ling,Ji, Sen,Fang, Zhen,Zhang, Guo,Wang, Li-Jiao,Zhong, Jie-Min,Xiong, Yu,Wang, Jiang-Hong,Huang, Shen-Zhen,Li, Lin-Li,Xiang, Rong,Niu, Dawen,Chen, Ying-Chun,Yang, Sheng-Yong
-
supporting information
p. 8293 - 8305
(2016/10/03)
-
- PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES
-
The invention relates to pyrrolone compounds of the formula (I) wherein X, Ra, Rb, Rc, R1, R2 and R3 are as defined in the specification. Furthermore, the present invention relates to processes and intermediates for making compounds of formula (I), to herbicidal compositions comprising these compounds and to methods of using these compounds to control plant growth.
- -
-
Page/Page column 41; 42
(2015/02/25)
-
- DIHYDRO-HYDANTOIN DERIVATIVES WITH HERBICIDAL ACTIVITY
-
The invention relates to substituted dihydro-hydantoin derivatives of the formula (I) wherein X, Ra, Rb, Rc, R1, R2 and R3 are as defined in the specification. Furthermore, the present invention relates to processes and intermediates for making compounds of formula (I), to herbicidal compositions comprising these compounds and to methods of using these compounds 10 to control or inhibit plant growth.
- -
-
Page/Page column 14; 47
(2015/07/15)
-
- Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1, 1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E
-
The Ras/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway plays a central role in the regulation of cell growth, differentiation, and survival. Expression of mutant BRAFV600E results in constitutive activation of the MAPK pathway, which can lead to uncontrolled cellular growth. Herein, we describe an SAR optimization campaign around a series of quinazoline derived BRAFV600E inhibitors. In particular, the bioisosteric replacement of a metabolically sensitive tert-butyl group with fluorinated alkyl moieties is described. This effort led directly to the identification of a clinical candidate, compound 40 (CEP-32496). Compound 40 exhibits high potency against several BRAFV600E-dependent cell lines and selective cytotoxicity for tumor cell lines expressing mutant BRAFV600E versus those containing wild-type BRAF. Compound 40 also exhibits an excellent PK profile across multiple preclinical species. In addition, significant oral efficacy was observed in a 14-day BRAFV600E-dependent human Colo-205 tumor xenograft mouse model, upon dosing at 30 and 100 mg/kg BID.
- Rowbottom, Martin W.,Faraoni, Raffaella,Chao, Qi,Campbell, Brian T.,Lai, Andiliy G.,Setti, Eduardo,Ezawa, Maiko,Sprankle, Kelly G.,Abraham, Sunny,Tran, Lan,Struss, Brian,Gibney, Michael,Armstrong, Robert C.,Gunawardane, Ruwanthi N.,Nepomuceno, Ronald R.,Valenta, Ianina,Hua, Helen,Gardner, Michael F.,Cramer, Merryl D.,Gitnick, Dana,Insko, Darren E.,Apuy, Julius L.,Jones-Bolin, Susan,Ghose, Arup K.,Herbertz, Torsten,Ator, Mark A.,Dorsey, Bruce D.,Ruggeri, Bruce,Williams, Michael,Bhagwat, Shripad,James, Joyce,Holladay, Mark W.
-
scheme or table
p. 1082 - 1105
(2012/04/04)
-
- COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS
-
The invention provides a novel compound having a structure corresponding to Formula (I): (A)-(B)-(C)-(D) or a pharmaceutically acceptable salt or prodrug thereof and methods for using them.
- -
-
Page/Page column 71
(2012/01/14)
-
- The design and synthesis of novel α-ketoamide-based p38 MAP kinase inhibitors
-
We have identified a novel series of potent p38 MAP kinase inhibitors through structure-based design which due to their extended molecular architecture bind, in addition to the ATP site, to an allosteric pocket. In vitro ADME and in vivo PK studies show these compounds to have drug-like characteristics which could result in the development of an oral treatment for inflammatory conditions.
- Montalban, Antonio Garrido,Boman, Erik,Chang, Chau-Dung,Ceide, Susana Conde,Dahl, Russell,Dalesandro, David,Delaet, Nancy G.J.,Erb, Eric,Ernst, Justin T.,Gibbs, Andrew,Kahl, Jeffrey,Kessler, Linda,Lundstroem, Jan,Miller, Stephen,Nakanishi, Hiroshi,Roberts, Edward,Saiah, Eddine,Sullivan, Robert,Wang, Zhijun,Larson, Christopher J.
-
p. 1772 - 1777
(2008/09/20)
-
- Microwave-assisted synthesis of N-pyrazole ureas and the p38α inhibitor BIRB 796 for study into accelerated cell ageing
-
Microwave irradiation of substituted hydrazines and β-ketoesters gives 5-aminopyrazoles in excellent yield, which can be transformed to the corresponding N-carbonyl derivatives by treatment with an isocyanate or chloroformate. Derivatization of 4-nitronaphth-1-ol using predominantly microwave heating methods and reaction with an N-pyrazole carbamate provides a rapid route to the N-pyrazole urea BIRB 796 in high purity, as a potent and selective inhibitor of p38α mitogen-activated protein kinase for the study of accelerated ageing in Werner syndrome cells. The Royal Society of Chemistry 2006.
- Bagley, Mark C.,Davis, Terence,Dix, Matthew C.,Widdowson, Caroline S.,Kipling, David
-
p. 4158 - 4164
(2008/09/19)
-
- Composition for dyeing keratin fibers which contain at least one diaminopyrazole, dyeing process, novel diaminopyrazoles and process for their preparation
-
The invention relates to novel compositions for the oxidation dyeing of keratin fibers, comprising at least one specific diaminopyrazole derivative, to the dyeing process using this composition, to novel diaminopyrazole derivatives and to a process for their preparation.
- -
-
Page column 20
(2008/06/13)
-